Possible Less Interest
Samsung Biologics conducts demand forecasting for institutional investors on October 26 and 27 before general cash offering scheduled for November 2 and 3. Doosan Bobcat’s demand forecasting, in the meantime, is scheduled for November 3 and 4.
Under the circumstances, some are saying that Samsung Biologics’ IPO schedule could affect that of Doosan Bobcat although Korea Investment & Securities, which is in charge of the IPO of Doosan Bobcat, said on October 16 that the two IPO cases are unlikely to affect each other.
“In a case where the two cases are underway at the same time, investors will prefer that with a higher level of profitability,” said a local fund manager, adding, “Investors interested in both Samsung Biologics and Doosan Bobcat cannot but take part in the demand forecasting after lowering the offer price for the latter.”
Samsung Biologics is expected to record a public offering of 2.25 trillion won or so and the amount is estimated at approximately one trillion won for Doosan Bobcat. Earlier, Doosan Bobcat’s public offering schedule was forecast to resume early next year but the earlier-than-expected resumption is likely to affect the relatively smaller company.